Head-To-Head Analysis: Autonomix Medical (NASDAQ:AMIX) and PROCEPT BioRobotics (NASDAQ:PRCT)

Autonomix Medical (NASDAQ:AMIX) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Profitability

This table compares Autonomix Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	N/A	N/A
PROCEPT BioRobotics	-77.75%	-46.59%	-30.63%

Institutional and Insider Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 19.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Autonomix Medical and PROCEPT BioRobotics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$3.11 million	N/A	N/A
PROCEPT BioRobotics	$136.19 million	19.56	-$105.90 million	($2.24)	-23.14

Autonomix Medical has higher earnings, but lower revenue than PROCEPT BioRobotics.

Analyst Ratings

This is a summary of current ratings and recommmendations for Autonomix Medical and PROCEPT BioRobotics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	0	0	0	0	N/A
PROCEPT BioRobotics	0	0	6	0	3.00

PROCEPT BioRobotics has a consensus price target of $46.00, suggesting a potential downside of 11.25%. Given PROCEPT BioRobotics’ higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Autonomix Medical.

Summary

PROCEPT BioRobotics beats Autonomix Medical on 5 of the 9 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.